金斯瑞(01548.HK)附屬引入鎮江高新關聯公司 涉資逾2.9億元
金斯瑞生物科技(01548.HK)公布,其間接非全資附屬Probio Cayman向B輪投資者鎮江高新創業投資配售5,731.4萬股B類優先股,總代價約為3,725.41萬美元(約2.92億港元)。所得款項淨額擬用於資本開支及其他一般營運資金用途,主要用於擴大生產設施、加強研發平台,以及一般公司開支。
完成後,金斯瑞於Probio Cayman的持股量,將由82.95%攤薄至80.34%。Probio集團提供抗體藥物發現、生物製劑臨床前開發、生物製劑臨床及商業生產、臨床前至商業生產階段治療用質粒及病毒開發等四大類綜合CDMO服務。
鎮江高新創業投資為鎮江高新的關聯公司,後者為江蘇瀚瑞投資控股的全資附屬,而江蘇瀚瑞投資控股為由中國鎮江市人民政府全資擁有的國有企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.